MT-act ambitions to become the leading company providing new chemical entities that safely restore the defects of the skeleton of our cells in chronic diseases. We developed MT-discover®, a unique modular discovery platform to extract an untapped pharmaceutical space named the ‘Tubulin Code’. The modular scalable platform delivered the first lead compound to become a transformative treatment in hypertrophic cardiomyopathy. The company employs 6 FTEs and is hosted on the CNRS campus in Montpellier (France) granting access to cutting-edge equipment and resources.
MT-act is a preclinical stage CNRS spin-off that ambitions to become the leading company that safely corrects defects of the skeleton of our cells. We are agnostic on the therapeutic focus: as specialists of the cytoskeleton, we use a science and evidenced-based view to identify new therapeutic targets within a totally untapped pharmaceutical space known to be causative for onset and progression of chronic diseases. To extract this untapped pharmaceutical space, we developed a breakthrough modular platform called ‘MT-discover®’ that delivers unique protected assets targeting tubulin-modifying enzymes associated with diseases with high unmet medical and societal needs.
MT-act is a preclinical stage CNRS spin-off that ambitions to become the leading company that safely corrects defects of the skeleton of our cells. We are agnostic on the therapeutic focus: as specialists of the cytoskeleton, we use a science and evidenced-based view to identify new therapeutic targets within a totally untapped pharmaceutical space known to be causative for onset and progression of chronic diseases. To extract this untapped pharmaceutical space, we developed a breakthrough modular platform called ‘MT-discover®’ that delivers unique protected assets targeting tubulin-modifying enzymes associated with diseases with high unmet medical and societal needs.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
